UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007028
Receipt number R000008293
Scientific Title Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy
Date of disclosure of the study information 2012/01/06
Last modified on 2012/01/06 18:03:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy

Acronym

Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy

Scientific Title

Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy

Scientific Title:Acronym

Assessing the efficacy of changing to Travoprost/Timolol fixed combination, as replacement therapy in patients on prostaglandin monotherapy

Region

Japan


Condition

Condition

Glaucoma

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to assess
the efficacy of changing to Travoprost/Timolol fixed combination in patients with glaucoma or ocular hypertension,who can not achieve target IOP while on their current IOP-lowering
monotherapy(travoprost, tafluprost,
latanoprost, bimatoprost).

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Efficacy
IOP value;IOP-lowering effect from baseline(reduced value;reduction rate%)

Key secondary outcomes

Safety
1.Ocular safety assessment:
Conjunctival hyperemia,adverse events
2.Systemic safety assessment:
Blood pressure,the pulse,adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Travoprost/Timolol fixed combination ophthalmic solution for 3 months

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Age at the time of the agreement 20 years old or older.
2.Gender and outpatient or the hospitalization are no object.
3.Must have been treated monotherapy with PGAs for 3 months or longer for the study eye, by the time of baseline examinations.
4.Patients who are judged to require the switch of Duotrav with be not able to achieve target IOP as on their current IOP-lowering monotherapy

Key exclusion criteria

1.Complications with chronic or recurrent uveitis,scleritis,or corneal herpes.
2.History of ocular trauma or intraocular conventional surgery or laser ocular surgery in the study eye within 3 months before baseline examinations.
3.Any abnormality preventing reliable applanation tonometer in the study eye.
4.Known medical history of allergic to PGAs or beta-blockers. 5.Contraindication of beta-blockers
6.Patients using an IOP-lowering drug other than those to be used in the study.
7.Patients using systemic administration of an oral CAI (Diamox,etc.)
8.Patient having serious eyes complications
9.Women who are pregnant or lactating
10.Severe dementia
11.Patients who are judged to be inappropriate for participation in the study for other reason by the doctor in charge.

Target sample size

180


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Keiji Yoshikawa

Organization

Yoshikawa Eye Clini

Division name

Ophthalmology Director

Zip code


Address

1-3-1 Nakamachi Machida-city Tokyo

TEL

042-739-0781

Email



Public contact

Name of contact person

1st name
Middle name
Last name Tadashi Nakano

Organization

The Jikei University

Division name

Ophthalmology

Zip code


Address

3-19-18Nishishinbashi minato-ku

TEL

03-3433-1111

Homepage URL


Email

tnakano@jikei.ac.jp


Sponsor or person

Institute

I.CHANGE study group

Institute

Department

Personal name



Funding Source

Organization

Japan Association of Health Service Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

吉川眼科クリニック(東京都)、東北大学(宮城県)、南松山病院(愛媛県)、東京慈恵会医科大学(東京都)


Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2011 Year 06 Month 21 Day

Date of IRB


Anticipated trial start date

2011 Year 12 Month 01 Day

Last follow-up date

2012 Year 12 Month 01 Day

Date of closure to data entry

2013 Year 01 Month 01 Day

Date trial data considered complete

2013 Year 02 Month 01 Day

Date analysis concluded

2013 Year 03 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 01 Month 06 Day

Last modified on

2012 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008293


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name